A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer’s disease and in adults with Down syndrome (ABATE)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2022
This article has no abstract
Epistemonikos ID: a1d9ae6762e778ac6ee7adf0325eedb030430445
First added on: Mar 21, 2025